One of the more impressive re-brandings of a Life Science company that I've seen in recent years is Kazia Therapeutics, formerly Novogen. This company changed its name in late 2017 to reflect the acquisition from Genentech of an impressive new lead compound called GDC-0084, for the treatment of glioblastoma. We published on this drug and Kazia's other programmes in a research note from 7 November 2017, prior to the name change. We've since updated that note in the light of the initiation of GDC-0084's Phase 2 study. You can download a copy of NDF Research's initiation report by clicking here or visiting Note - the usual disclaimers apply - click here.


Kazia Therapeutics has rallied since late 2017